All News

Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x

Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in…

BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK

Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy

Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL, aB2GP IgG higher risk, higher titers (>40U) @RheumNow https://t.co/rcQaqrtDN5

The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA C…

Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL

Excess of Rare Deleterious Variants Within JAK-STAT Pathway - Related Genes in …

#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8

RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL

Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Exte…

Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae

Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric …

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Obstetric domain redefined Added: ⭐️Cardiac thickening/vegetation ⭐️Thrombocytopenia @Rheumnow https://t.co/Me2jrnvalU

Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA

The Association Between Sonographic Enthesitis with Sonographic Synovitis and T…

Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8

Does Evusheld shield people living with rheumatic diseases? | RheumNow

Uggh! What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE

Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F

How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients wit…

Lower socioeconomic status (cluster 1) patients: ● older age at the diagnosis (37.9 vs. 32.6) ● longer diagnosis delay (7.8 vs. 6.8 years) ● higher BMI (27.6 vs. 25.9) ● greater structural damage vs cluster 2 Lopez-Medina C Abs0376 https://t.co/wXOksFGDKl #ACR22 @RheumNow https://t.co/1YVRA6r1sw

The Socioeconomic Profile of Patients with Radiographic Axial Spondyloarthritis…

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Novel Aspects Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles Microvasc - Suspected/Established @RheumNow https://t.co/M8NWRSyH4p

#abs1235 #acr22 @rheumnow articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh

PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf

Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs…

🌟PSA vs RA 🌟 -UK cohort PSA associated with: 👉⬆️ duration symptoms prior 2 referral 👉⬆️ interval between GP presentation and DX 👉⬇️DMARD commencement 👉⬇️ improvement in Dx activity @ 3/12 # We need to do better #ACR22 Abst#1613 @RheumNow

Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also ➣ more comorbidities ➣ higher prevalence of smoking ➣ worse disease activity ➣ higher use of anti-rheumatic drugs Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx

Opioid Use and Healthcare Utilization in Adults with PsA and AS - ACR Meeting A…

Topics

All News

Do you get our email newsletter?